

Jazz Pharmaceuticals plc
 Form 3
 August 07, 2014

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â McGill Iain		(Month/Day/Year)	Jazz Pharmaceuticals plc [JAZZ]	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
		07/31/2014		
C/O JAZZ PHARMACEUTICALS PLC,Â CONNAUGHT HOUSE, 1 BURLINGTON RD, FL. 4			(Check all applicable)	
(Street)			<input type="checkbox"/> Director	<input type="checkbox"/> 10% Owner
			<input checked="" type="checkbox"/> Officer	<input type="checkbox"/> Other
			(give title below) (specify below)	
			Head of EUSA Int'l & SVP	
			6. Individual or Joint/Group Filing(Check Applicable Line)	
			<input checked="" type="checkbox"/> Form filed by One Reporting Person	
			<input type="checkbox"/> Form filed by More than One Reporting Person	

DUBLIN 4,Â L2Â
 (City) (State) (Zip)

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	27,553 ⁽¹⁾	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security	4. Conversion or Exercise	5. Ownership Form of	6. Nature of Indirect Beneficial Ownership
---	---	--	---------------------------	----------------------	--

Edgar Filing: Jazz Pharmaceuticals plc - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	(Instr. 5)
Nonstatutory Stock Option (right to buy)	Â (2)	08/08/2022	Ordinary Shares	22,500	\$ 46.83	D	Â
Nonstatutory Stock Option (right to buy)	Â (3)	03/04/2023	Ordinary Shares	8,500	\$ 59.13	D	Â
Nonstatutory Stock Option (right to buy)	Â (4)	02/26/2024	Ordinary Shares	11,500	\$ 166.62	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
McGill Iain C/O JAZZ PHARMACEUTICALS PLC CONNAUGHT HOUSE, 1 BURLINGTON RD, FL. 4 DUBLIN 4, Â L2 Â	Â	Â	Â Head of EUSA Int'l & SVP	Â

Signatures

/s/ Larissa Schwartz as attorney in fact for Iain McGill
08/07/2014

__Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Including 25,250 restricted stock units ("RSUs") granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share upon the vesting of the unit. Of the 25,250 RSUs, 15,000 RSUs vest in three equal annual installments from August 9, 2014 to August 9, 2016, 4,500 RSUs vest in three equal annual installments from March 5, 2015 to March 5, 2017, and 5,750 RSUs vest in four equal annual installments from February 27, 2015 to February 27, 2018.
 - (2) This option was granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to this option vested with respect to 1,666 shares and vest with respect to 20,834 shares in equal monthly installments from August 9, 2014 to August 9, 2016.
 - (3) This option was granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to this option vested with respect to 750 shares and vest with respect to 7,750 shares in equal monthly installments from September 5, 2014 to March 5, 2017.
 - (4) This option was granted pursuant to the Issuer's 2011 Equity Incentive Plan. 1/4th of the ordinary shares subject to this option vest on February 27, 2015 and the remainder vest in equal monthly installments from March 27, 2015 to February 27, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.